DepressionNCT07654179
Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation
A study testing Metformin and Antidepressant Therapy in people with Depression and Depressive Disorder, run by Riphah International University at 2 sites in Pakistan.
Trial summary
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Depression, Depressive Disorder, Overweight or Obesity
- What is being tested?
- Metformin and Antidepressant Therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 2 sitesPakistan
- Study dates
- 17 Jun 2026to 11 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
INCLUSION CRITERIA Group I: Normal Controls Group II: Depression Group III: Obesity
Group IV and V:
- Age ≥ 18 years
- Both males and females
- Recurrent depressive disorder (6A71) according to ICD-11,
- Asian cut off: Obese and overweight (BMI < 23)
- BDI score ≥ 13 or PHQ score ≥ 4
- Either medication-naïve or medication-free for at least 2 weeks before enrollment, or the patient did not take antidepressants during the last 7 days before study entry (discontinuation of effective medication to enable study participation is prohibited)
- In case of non-psychotropic medication: The patient received stable pharmacological medication for at least 14 days before study entry (any changes in medication dose or frequency of therapy must be answered with no)
EXCLUSION CRITERIA Groups I-III: Negative Controls (Normal: no depression and Obesity for SNP comparison only)
- Age less than 18
- Dementia/ Mentally impaired who can not fill self report performas for inclusion criteria
Group IV: Positive Control (RCT patients)
- Patients with comorbid conditions (HTN, CKD) if taking any drug for that condition.
- The patient is not an employee of the investigator study site, or a family member of the employees or the investigator, or otherwise dependent on the sponsor, the investigator, or the investigator study site.
- The patient did not participate in other interventional trials during the 6 months before and at the time of this trial. The patient does not have a history of non-response to antidepressants included in the study.
- The patient has not given birth within the 6 months before study entry and is not breastfeeding
- The patient did not receive treatment with ketamine, irreversible MAO inhibitor (e.g. tranylcypromine), electroconvulsive therapy (ECT) or other stimulatory treatments in the index episode.
- The patient is not diagnosed with dementia and does not have moderate or severe impairment of general cognitive function according to clinical impression.
- The patient does not meet the criteria for alcohol use disorder (DSM-5: 303.90; ICD-10: F10.20) or substance use disorder (DSM-5: 304; ICD-10: F11.20 - F19.20) in DSM-5, and a urine/serum drug screening is negative (except for benzodiazepines and opiates).
- The patient does not have:
- A known allergy or contraindication against antidepressants included in the study
- History of suicidal tendencies
- Uncontrolled hepatic disorder, renal or cardiovascular disease
- DM
- Untreated hypothyroidism
- History of myocardial infarction or stroke
- Symptomatic peripheral arterial disease
- Monogenic familial hypercholesterolemia
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan2 sites, 2 recruiting
- Recruiting
Pakistan Railway Hospital
Rawalpindi, Punjab Province, 44000
Siddique, MBBS, M.Phil, +923175441910, dr.afifa.siddique@gmail.com
Farooq, MBBS, M.Phil, +92 333 5244374, drafifa.one@gmail.com
- Recruiting
Afifa Siddique
Rawalpindi, Punjab Province
AFIFA Siddique, PhD Scholar, MBBS, MPhil, +923175441910, Dr.afifa.siddique@gmail.com
Afifa Siddique, MBBS, Mphil, +923448568632, drafifa.one@gmail.com
About this study
Official title: Efficacy of Metformin With Antidepressant Medication as Adjunct Therapy in Depression-obesity Ccomorbidity and Ssociation With NEGR1/RPL31P12 Variants Based on Genotyping
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.
Read the detailed description
There is a substantial percentage of the Pakistani population who are both overweight/obese and depressed, with estimates from clinical samples averaging 25%. So, the personalized treatment approach for depression and obesity needs to be explored.
Obesity and depression commonly coexist and are associated with poorer health outcomes. Metformin, widely used for metabolic disorders and obesity, has shown potential antidepressant effects. However, evidence on its use as an adjunct to antidepressant therapy in patients with depression-obesity comorbidity remains limited, and the influence of genetic variants on treatment response is not well understood. This study aims to evaluate the effectiveness of adjunctive metformin and its association with NEGR1 and RPL31P12 genetic variants in this population.
- Being tested
- Metformin, Antidepressant Therapy
- Medical subject headings
- Depression, Depressive Disorder, Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MetforminDrug
Also called Trade names: Glucophage, Neodipar
Tab 500-2000 mg/day (500 mg BD to 1000 mg BD)
Antidepressant TherapyDrug
Also called Sertraline hydrochloride, Bupropion hydrochloride,
Sertraline 50 mg/day or Duloxetine 60 mg/day or Bupropion XL 150-300 mg/day
| Study group | Role | What they receive |
|---|---|---|
| Antidepressant Monotherapy | Active comparator | Tab Sertraline 50 mg/day or Cap Duloxetine 60 mg/day or Tab Bupropion XL 150-300 mg/day Receives: Drug: Antidepressant Therapy |
| Adjunctive Metformin Therapy | Experimental | Tab Sertraline 50 mg/day + Metformin or Cap Duloxetine 60 mg/day + Metformin or Tab Bupropion XL 150-300 mg/day + Metformin Receives: Drug: Metformin; Drug: Antidepressant Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Severity of the depression
The change in the total PHQ-9 score between baseline and 4-weeks follow-up is the primary outcome measure. This measure is a patient-rated inventory of depressive symptoms. All items are scored on scales ranging from 0-3 and the sum of the scores provides the total score for the measure. On this scale, higher scores indicate poorer outcomes. Scores 9-19 and 20-27 are considered moderate and severe depression respectively.
Measured: 1 month
Change in BMI
Change in Body Mass Index (BMI): BMI will be measured at baseline and study completion and calculated as weight in kilograms divided by height in meters squared (kg/m²). The outcome will be assessed as the change in BMI from baseline.
Asian BMI Classification:
Underweight: < 18.5 kg/m² Normal weight: 18.5-22.9 kg/m² Overweight: 23.0-24.9 kg/m² Obesity Class I: 25.0-29.9 kg/m² Obesity Class II: ≥ 30.0 kg/m²
BMI reduction < 1 kg/m²: Minimal change BMI reduction ≥ 1 kg/m²: Clinically meaningful improvement Weight loss ≥ 5% of baseline body weight: Clinically significant weight reduction associated with metabolic health benefits.
A decrease in BMI from baseline and/or movement to a lower BMI category will be considered indicative of improvement in obesity-related outcomes.
Measured: 3 months
Secondary outcomes (6)
Change in Blood Pressure
Change in Blood Pressure: Blood pressure will be measured in mmHg at baseline, 14 days, 28 days, one month and 3 months.. The outcome will be assessed as the change in systolic and diastolic blood pressure from baseline. Normal blood pressure is <120/80 mmHg, elevated blood pressure is 120-129/<80 mmHg, and high blood pressure is ≥130/80 mmHg. A reduction in blood pressure values from baseline will indicate improvement in cardiovascular health status.
Measured: 3 months
Change in Blood Sugar Levels
Change in Blood Sugar: Blood glucose levels will be measured at baseline, 14 days, 28 days, one month and 3 months. The outcome will be assessed as the change in blood glucose from baseline. Normal fasting blood glucose is 70-99 mg/dL, prediabetes is 100-125 mg/dL, and diabetes is ≥126 mg/dL. A reduction in blood glucose levels toward the normal range will indicate improvement in glycemic control, whereas increase will be monitored for safety
Measured: 3 months
Change in Renal Function tests
Change in Renal Function Tests: Renal function will be monitored by measuring serum creatinine and blood urea levels at baseline and study completion. The outcome will be assessed as the change in these parameters from baseline. Normal serum creatinine is approximately 0.6-1.2 mg/dL, while values >1.2 mg/dL may indicate impaired renal function. Normal blood urea is approximately 15-40 mg/dL, while values >40 mg/dL may suggest reduced kidney function or impaired renal clearance. An increase in serum creatinine or blood urea from baseline will be considered indicative of deterioration in renal function, whereas stable values within the normal range will indicate preserved renal function.
Measured: 3 months
Change in Liver Function tests
Change in Liver Function Tests (LFTs): Liver function will be monitored at baseline and study completion. The outcome will be assessed as the change in liver enzyme levels and bilirubin from baseline.
Alanine Aminotransferase (ALT): Normal 7-56 U/L; elevated >56 U/L may indicate liver injury.
Aspartate Aminotransferase (AST): Normal 10-40 U/L; elevated >40 U/L may indicate hepatic or muscle injury.
Alkaline Phosphatase (ALP): Normal 44-147 U/L; elevated >147 U/L may suggest cholestatic liver disease or biliary obstruction.
Total Bilirubin: Normal 0.2-1.2 mg/dL; elevated >1.2 mg/dL may indicate impaired liver function or biliary obstruction.
Albumin: Normal 3.5-5.0 g/dL; decreased <3.5 g/dL may indicate impaired hepatic synthetic function.
Measured: 3 months
C - Reactive Proteins levels
Change in C-Reactive Protein (CRP) Levels: CRP levels will be measured at baseline and study completion to assess systemic inflammation. The outcome will be assessed as the change in CRP levels from baseline.
Normal: < 3 mg/L Mildly elevated: 3-10 mg/L Moderately elevated: 10-50 mg/L Markedly elevated: > 50 mg/L Severely elevated: > 100 mg/L
Decrease in CRP level: Indicates reduction in systemic inflammation. Stable CRP within normal range (< 3 mg/L): Indicates absence of significant inflammation.
Increase in CRP above normal range: Suggests worsening or persistent inflammatory activity.
Measured: 3 months
Lipid Profile
It will be measured at baseline and study completion to monitor safety of combination therapy.
Total Cholesterol (TC): Desirable: < 200 mg/dL, Borderline high: 200-239 mg/dL, High: ≥ 240 mg/dL Low-Density Lipoprotein Cholesterol (LDL-C): Optimal: < 100 mg/dL, Near optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Very high: ≥ 190 mg/dL High-Density Lipoprotein Cholesterol (HDL-C): Low: < 40 mg/dL (men), < 50 mg/dL (women), Protective: ≥ 60 mg/dL Triglycerides (TG): Normal: < 150 mg/dL, Borderline high: 150-199 mg/dL, High: 200-499 mg/dL, Very high: ≥ 500 mg/dL
Interpretation:
Decrease in TC, LDL-C, and TG levels indicates improvement in lipid metabolism. Increase in HDL-C levels indicates a favorable cardiovascular risk profile. Lipid values remaining within the normal range throughout the study will be considered indicative of metabolic safety of the combination therapy.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start17 Jun 2026
- Primary completion11 Jun 2027 (estimated)
- Study completion11 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for DepressionStudies of the same condition, open and under way.
- More trials run by Riphah International UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Total 5 groups: 1. Three groups will be negative control, assessed for genetic variants only, and not included in RCT. normal subjects, depression, or obesity (each n=90). 2. Comorbid depression-obesity will be positive control. RCT will be conducted on this group (n=180), and they will be divided into two main groups. Group 1 (n = 90) will receive sertraline, duloxetine, or bupropion monotherapy (groups A, B, and C - 30 patients each). Group 2 (n = 90) will similarly be subdivided into three groups A', B', and C' (30 patients each). They will receive sertraline, duloxetine, or bupropion in combination with metformin. Group 2 combinations: Tab Metformin + Tab sertraline Tab Metformin + Cap. duloxetine Tab Metformin + Tab bupropion
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Riphah International University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Afifa,Siddique, PhD Scholar, MBBS, M.Phil, Principal investigator, Islamic International Medical College, Riphah International University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07654179
- Sponsor's protocol ID
- Riphah/IIMC/ IRB/26/1049
- Status last verified
- Aug 2026
- First submitted
- 13 Jun 2026
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Siddique A, Naeem U, Masood Khokhar M, Waheed Syed A, Iftikhar J, Amjad A. Impact of Demographic Factors on the Treatment Response of Antidepressant Therapy: A Descriptive Cohort Study from Pakistan. Tunis Med. 2025 Feb 5;103(2):201-205. doi: 10.62438/tunismed.v103i2.5280.
PubMed 40096719Ninomiya-Baba M, Matsuo J, Sasayama D, Hori H, Teraishi T, Ota M, Hattori K, Noda T, Ishida I, Shibata S, Kunugi H. Association of body mass index-related single nucleotide polymorphisms with psychiatric disease and memory performance in a Japanese population. Acta Neuropsychiatr. 2017 Oct;29(5):299-308. doi: 10.1017/neu.2016.66. Epub 2016 Dec 7.
PubMed 27923415Cheng YY, Yao Q, Miao Y, Guan W. Metformin as a potential antidepressant: Mechanisms and therapeutic insights in depression. Biochem Pharmacol. 2025 Mar;233:116773. doi: 10.1016/j.bcp.2025.116773. Epub 2025 Jan 31.
PubMed 39894309Choi WS, Song MK, Seo M, Woo YS, Bahk WM. Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients. Ther Adv Psychopharmacol. 2026 Feb 18;16:20451253261419609. doi: 10.1177/20451253261419609. eCollection 2026.
PubMed 41727810
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Metformin With Antidepressant Medication as Adjunct Therapy in Depression-obesity Ccomorbidity and Ssociation With NEGR1/RPL31P12 Variants Based on Genotyping
- ClinicalTrials.gov ID
- NCT07654179
- Acronym / sponsor ID
- Riphah/IIMC/ IRB/26/1049
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Riphah International UniversityUniversity, hospital or other
- Study start
- 17 Jun 2026 (actual)
- Primary completion
- 11 Jun 2027 (estimated)
- Study completion
- 11 Jun 2027 (estimated)
- First posted
- 17 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.
Detailed description
There is a substantial percentage of the Pakistani population who are both overweight/obese and depressed, with estimates from clinical samples averaging 25%. So, the personalized treatment approach for depression and obesity needs to be explored.
Obesity and depression commonly coexist and are associated with poorer health outcomes. Metformin, widely used for metabolic disorders and obesity, has shown potential antidepressant effects. However, evidence on its use as an adjunct to antidepressant therapy in patients with depression-obesity comorbidity remains limited, and the influence of genetic variants on treatment response is not well understood. This study aims to evaluate the effectiveness of adjunctive metformin and its association with NEGR1 and RPL31P12 genetic variants in this population.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Total 5 groups: 1. Three groups will be negative control, assessed for genetic variants only, and not included in RCT. normal subjects, depression, or obesity (each n=90). 2. Comorbid depression-obesity will be positive control. RCT will be conducted on this group (n=180), and they will be divided into two main groups. Group 1 (n = 90) will receive sertraline, duloxetine, or bupropion monotherapy (groups A, B, and C - 30 patients each). Group 2 (n = 90) will similarly be subdivided into three groups A', B', and C' (30 patients each). They will receive sertraline, duloxetine, or bupropion in combination with metformin. Group 2 combinations: Tab Metformin + Tab sertraline Tab Metformin + Cap. duloxetine Tab Metformin + Tab bupropion
| Arm | Type | Receives |
|---|---|---|
| Antidepressant Monotherapy | Active comparator | Drug: Antidepressant TherapyTab Sertraline 50 mg/day or Cap Duloxetine 60 mg/day or Tab Bupropion XL 150-300 mg/day |
| Adjunctive Metformin Therapy | Experimental | Drug: Metformin, Drug: Antidepressant TherapyTab Sertraline 50 mg/day + Metformin or Cap Duloxetine 60 mg/day + Metformin or Tab Bupropion XL 150-300 mg/day + Metformin |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MetforminAlso: Trade names: Glucophage, NeodiparTab 500-2000 mg/day (500 mg BD to 1000 mg BD) | Drug | Adjunctive Metformin Therapy |
| Antidepressant TherapyAlso: Sertraline hydrochloride, Bupropion hydrochloride,Sertraline 50 mg/day or Duloxetine 60 mg/day or Bupropion XL 150-300 mg/day | Drug | Adjunctive Metformin Therapy, Antidepressant Monotherapy |
Primary outcome
Change in Severity of the depression
Time frame: 1 month
The change in the total PHQ-9 score between baseline and 4-weeks follow-up is the primary outcome measure. This measure is a patient-rated inventory of depressive symptoms. All items are scored on scales ranging from 0-3 and the sum of the scores provides the total score for the measure. On this scale, higher scores indicate poorer outcomes. Scores 9-19 and 20-27 are considered moderate and severe depression respectively.
Change in BMI
Time frame: 3 months
Change in Body Mass Index (BMI): BMI will be measured at baseline and study completion and calculated as weight in kilograms divided by height in meters squared (kg/m²). The outcome will be assessed as the change in BMI from baseline. Asian BMI Classification: Underweight: < 18.5 kg/m² Normal weight: 18.5-22.9 kg/m² Overweight: 23.0-24.9 kg/m² Obesity Class I: 25.0-29.9 kg/m² Obesity Class II: ≥ 30.0 kg/m² BMI reduction < 1 kg/m²: Minimal change BMI reduction ≥ 1 kg/m²: Clinically meaningful improvement Weight loss ≥ 5% of baseline body weight: Clinically significant weight reduction associated with metabolic health benefits. A decrease in BMI from baseline and/or movement to a lower BMI category will be considered indicative of improvement in obesity-related outcomes.
6 secondary outcomes
Change in Blood Pressure
Time frame: 3 months
Change in Blood Sugar Levels
Time frame: 3 months
Change in Renal Function tests
Time frame: 3 months
Change in Liver Function tests
Time frame: 3 months
C - Reactive Proteins levels
Time frame: 3 months
Lipid Profile
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
- Results publication: PubMed 40096719Siddique A, Naeem U, Masood Khokhar M, Waheed Syed A, Iftikhar J, Amjad A. Impact of Demographic Factors on the Treatment Response of Antidepressant Therapy: A Descriptive Cohort Study from Pakistan. Tunis Med. 2025 Feb 5;103(2):201-205. doi: 10.62438/tunismed.v103i2.5280.
- Results publication: PubMed 27923415Ninomiya-Baba M, Matsuo J, Sasayama D, Hori H, Teraishi T, Ota M, Hattori K, Noda T, Ishida I, Shibata S, Kunugi H. Association of body mass index-related single nucleotide polymorphisms with psychiatric disease and memory performance in a Japanese population. Acta Neuropsychiatr. 2017 Oct;29(5):299-308. doi: 10.1017/neu.2016.66. Epub 2016 Dec 7.
- Results publication: PubMed 39894309Cheng YY, Yao Q, Miao Y, Guan W. Metformin as a potential antidepressant: Mechanisms and therapeutic insights in depression. Biochem Pharmacol. 2025 Mar;233:116773. doi: 10.1016/j.bcp.2025.116773. Epub 2025 Jan 31.
- Results publication: PubMed 41727810Choi WS, Song MK, Seo M, Woo YS, Bahk WM. Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients. Ther Adv Psychopharmacol. 2026 Feb 18;16:20451253261419609. doi: 10.1177/20451253261419609. eCollection 2026.
- Individual participant dataSharing planned: No
Related trials for Depression
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Recruiting
Cultural Adaptation of an Online Parenting Intervention to Reduce the Risk of Depression and Anxiety in Adolescents
Risk of Depression and Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Afifa,Siddique, PhD Scholar, MBBS, M.Phil principal investigator
Islamic International Medical College, Riphah International University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Metformin and Antidepressant Therapy in people with Depression and Depressive Disorder, run by Riphah International University at 2 sites in Pakistan.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Afifa Siddique, PhD Scholar, MBBS, M.Phil (+923175441910, dr.afifa.siddique@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Severity of the depression (time frame: 1 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07654179, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.